Elicio Therapeutics (ELTX) Return on Capital Employed (2021 - 2026)
Elicio Therapeutics posted quarterly Return on Capital Employed of 220.46% for Q1 2026, up 5082.0% year-on-year from 4.25% in Q1 2025, and down 10.85% on a QoQ basis from 198.88% in Q4 2025.
Elicio Therapeutics (ELTX) has 6 years of Return on Capital Employed data on file, last reported at 220.46% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 5082.0% year-over-year to 220.46%; the trailing twelve-month figure through Mar 2026 stood at 220.46% (up 5082.0% YoY), and the FY2025 full-year result was 199.44%, up 7930.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 220.46%, down from 198.88% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.48% in Q3 2022 and bottomed at 329.83% in Q2 2024.
- The 5-year median for Return on Capital Employed is 189.13% (2025), against an average of 162.13%.
- The widest annual swing landed in 2024, when Return on Capital Employed sank 24473 bps; it then jumped 9398 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 92.39% in 2022, then plunged by 100 bps to 185.1% in 2023, then dropped by 12 bps to 206.73% in 2024, then advanced by 4 bps to 198.88% in 2025, then declined by 11 bps to 220.46% in 2026.
- The last three Return on Capital Employed figures came in at 220.46% (Q1 2026), 198.88% (Q4 2025), and 189.13% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -220.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -220.46% |
| Dec 31, 2025 | -198.88% |
| Sep 30, 2025 | -189.13% |
| Jun 30, 2025 | -235.85% |
| Mar 31, 2025 | -271.28% |
| Dec 31, 2024 | -206.73% |
| Sep 30, 2024 | -226.61% |
| Jun 30, 2024 | -329.83% |
| Mar 31, 2024 | -192.23% |
| Dec 31, 2023 | -185.10% |
| Sep 30, 2023 | -141.62% |
| Jun 30, 2023 | -85.10% |
| Mar 31, 2023 | -85.37% |
| Dec 31, 2022 | -92.39% |
| Sep 30, 2022 | -20.48% |
| Jun 30, 2022 | -32.00% |
| Mar 31, 2022 | -43.12% |
| Dec 31, 2021 | -42.76% |
| Sep 30, 2021 | -67.99% |
| Jun 30, 2021 | -56.93% |
| Mar 31, 2021 | -82.09% |